Therapeutic Exploratory (Phase II)

3,454 trials 1,368 recruiting

Filter these 3,454 trials by condition, country, sponsor and more.

Open in Search →

A Phase IIb, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Dirocaftor/Po… Ended

2022-500410-26-01 Cystic Fibrosis 2024-05-27
Open-label, prospective study to assess the safety, tolerability, analgesic effect and feasibility of IN SUF/KET in pediatric patients with … Ended

2023-504023-63-00 Pain 2024-05-24
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Ended

2022-502481-24-00 Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) 2024-05-23
A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma Ended

2023-507324-23-00 recurrent or persistent uterine serous carcinoma 2024-05-22
A study to evaluate safety and efficacy of two different concentrations of a new formulation of Recombinant Human Nerve Growth Factor (rhNGF… Ended

2023-507561-26-00 Dry Eye 2024-05-17
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis Ended

2023-506655-19-00 Ulcerative Colitis (UC) 2024-05-16
Tirzepatide, a new drug for type 2 diabetes mellitus and obesity, as a possible treatment to modify the clinical evolution of Wolfram syndro… Ended

2024-514909-64-00 Wolfram syndrome type 1 2024-05-16
A Single-blind, Phase 2, Multi-center, Randomized Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of the Relaxin Agonist… Ended

2023-503504-88-00 Hepatorenal Syndrome – Acute Kidney Injury 2024-05-13
A study to learn how safe starting vericiguat at a dose of 5 milligrams is in participants with chronic heart failure with reduced ejection … Ended

2023-507682-25-00 Chronic heart failure with reduced ejection fraction 2024-05-13
A Study to Evaluate the Safety and Effectiveness of ADX-914 in Subjects with Moderate to Severe Atopic Dermatitis Ended

2023-510238-10-00 Moderate to Severe Atopic Dermatitis 2024-05-13
A study to evaluate safety and efficacy of two different doses of Isocyclosporin A eye drop solution in patients with Atopic Keratoconjuncti… Ended

2023-508907-19-00 Atopic keratoconjunctivitis (AKC) 2024-05-10
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without T… Ended

2023-504583-42-00 Overweight or Obesity and Chronic Kidney Disease With o 2024-05-07
EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE Ended

2023-505083-11-01 Alzheimer's Disease 2024-05-07
A Study of the Efficacy, Safety, and Tolerability of KAN-101 in Participants With Celiac Disease Ended

2023-507240-37-00 celiac disease 2024-04-30
MYK-224 in Heart Failure with Preserved Ejection Fraction (HFpEF) Ended

2023-505919-21-00 Heart failure with preserved ejection fraction (HFpEF) 2024-04-25
A research study to see if kidney damage in people with chronic kidney disease and type 2 diabetes living with overweight or obesity can be … Ended

2023-505857-42-00 Chronic Kidney Disease, Type 2 diabetes 2024-04-19
A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants with Cirrhosis-ZEAL-UNLOCK Ended

2023-506893-11-00 Cirrhosis of the liver is a condition in which the live 2024-04-19
"TOPOLOGY" : A phase II study to evaluate the efficacy and toxicities of PLX038, in patients with locally advanced or metastatic triple-nega… Ended

2022-501507-27-00 Advanced or metastatic triple-negative breast cancer 2024-04-17
Proof-of-concept study evaluating subcutaneous amlitelimab in adult participants with moderate to severe hidradenitis suppurativa. Ended

2023-505803-22-00 Hidradenitis 2024-04-15
A Phase 2 Trial of BDC-1001 as Single Agent and in Combination with Pertuzumab in Subjects with Human Epidermal Growth Factor Receptor 2–Pos… Ended

2023-506038-65-00 HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE METAS 2024-04-15
A Phase 2 Study of CRD-4730 in CPVT Ended

2022-502845-83-00 Catecholaminergic Polymorphic Ventricular Tachycardia ( 2024-04-15
Efficacy and Safety of ANB032 in the Treatment of Subjects with Atopic Dermatitis Ended

2023-503522-40-01 Atopic Dermatitis 2024-04-10
A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinet… Ended

2023-505414-15-00 Dermatitis, Atopic 2024-04-10
PH2a, VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living with HIV-1 Ended

2023-507173-18-00 HIV Infections 2024-04-09